Diab, A., Ascierto, P. A., Maio, M., Abdel-Wahab, R., Negrier, S., Mortier, L., Arenberger, P., Dalle, S., Krajsova, I., Cruz, L. D. L., Leccia, M., Guida, M., Lebbé, C., Grob, J., Butler, M. O., In, G. K., Loquai, C., Walker, J. W., Atkinson, V., Kapiteijn, E., Haferkamp, S., Chunduru, S., Rahimian, S., Guidoboni, M., Robert, C. (2025). Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00727